Open Access

ARTICLE

Nimotuzumab Combined with Neoadjuvant or Induction Chemotherapy for Head and Neck Squamous Cell Carcinoma: A Retrospective Study

Huihui Zhang, Jing Yan, Xiaoyong Ren, Ying Sheng, Zhenghui Wang, Jianmin Liang, Yan Yan, Yangyang Jia, Zhihui Li, Jin Hou^*

Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

* Corresponding Author: Jin Hou. Email:

Oncologie 2022, 24(4), 707-716. https://doi.org/10.32604/oncologie.2022.027023

Received 10 October 2022; Accepted 06 December 2022; Issue published 31 December 2022

Abstract

Objective: To assess the efficacy and toxicity of nimotuzumab combined with neoadjuvant or induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Patients received intravenous nimotuzumab (400 mg, weekly for 1–3 weeks) combined with chemotherapy (5-fluorouracil/paclitaxel/docetaxel + nedaplatin/cisplatin for 1–2 cycles), prior to definitive surgical resection, radiotherapy or other treatments. The primary endpoint was the objective response rate (ORR). The secondary endpoints were tumor downstaging, complete response rate (CRR), partial response rate (PRR), disease control rate (DCR), R0 resection rate, pathological complete response (pCR), larynx preservation rate, overall survival (OS), progression-free survival (PFS), and safety. Results: A total of 71 HNSCC patients with T_1-4N_0-2M₀ were enrolled. After neoadjuvant/induction chemotherapy, the ORR in patients with hypopharyngeal and laryngeal cancer was 100% and 76.1%, respectively. The DCR was 100% in both groups. The T downstaging in patients with hypopharyngeal and laryngeal cancer was 64.0% and 50.0%, the N downstaging was 28.0% and 2.2% (p = 0.001), respectively. At the early stage and locally advanced stage, the T downstaging was 66.7% and 50.0%, the N downstaging was 0% and 16.0% (p = 0.128), respectively. The R0 resection rate and pCR in 39 patients receiving surgery were 94.9% and 20.5%, respectively. The larynx preservation rate was 73.2%. The median PFS was 29.2 months in patients with laryngeal cancer. A mild rash occurred in a single patient and no grade 4 adverse events were encountered. Conclusion: Nimotuzumab combined with neoadjuvant or induction chemotherapy achieved similar short-term efficacy and less adverse events compared with previous studies. The N downstaging rate in patients with hypopharyngeal cancer was significantly higher compared with patients with laryngeal cancer.

---

Keywords

---